 |
14 Diseases |  |
2 Trials |
|
2 Trials |  |
29 News |  |
- Computer simulation and quantification of the mass-action law-base pharmacodynamics parameters for anti-cancer and anti-viral therapeutics for single drugs and their combinations. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_178;
- | PTC607 / PTC Therap
New P1 trial: First in human clinical study of a novel drug PTC607 to assess effects of food intake and to compare PTC607 levels, when taken as an oral suspension and tablet formulation. (EUDRACT) - Sep 13, 2023
P1, N=8, Completed, Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd.
- | PTC607 / PTC Therap
Trial completion, Trial initiation date: First in human clinical study of a novel drug PTC607 to assess effects of food intake and to compare PTC607 levels, when taken as an oral suspension and tablet formulation. (EUDRACT) - Sep 13, 2023
P1, N=8, Completed, Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd.
Not yet recruiting --> Completed
- | PTC607 / PTC Therap
Trial completion: First in human clinical study of a novel drug PTC607 to assess its safety and tolerability in healthy volunteers (EUDRACT) - Sep 13, 2023
P1, N=40, Completed, Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd.
Not yet recruiting --> Completed Recruiting --> Completed
- | PTC607 / PTC Therap
Trial initiation date: First in human clinical study of a novel drug PTC607 to assess its safety and tolerability in healthy volunteers (EUDRACT) - Sep 1, 2023
P1, N=40, Recruiting, Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd.
Recruiting --> Completed Initiation date: Jan 2000 --> Jan 2023
- T900607 / Amgen
Investigation of novel nucleoside analogues as anticancer agents for the treatment of pancreatic cancer (Virtual-only (Zoom)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_8887;
PASS prediction and ADMET revealed these compounds as non toxic and non carcinogenic. These results suggested that these analogues can be proposed as potential candidates for the treatment of PDAC and are worth further in vitro and in vivo investigations.
- T900607 / Amgen, docetaxel / Generic mfg.
Mass-action law based general pharmacodynamics theory and algorithm for quantitative computer simulation of drug-evaluations in cells, in animals and in clinical trials (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1270;
Anti-cancer Combos (Taxotere+T607, against HCT-116 colon carcinoma xenograft in nude mice), both used only 10 data points and both achieved quantitative determination of Synergism. This report reaffirm Example 2 with the same drug combos against MX-1 mammary carcinoma xenograft in nude mice, using only 10 data points, showed similar synergy at ED75 to ED97, CI= 0.82-0.79 for MX-1, and CI= 0.98-0.64 for HCT-116.
- T900607 / Amgen, docetaxel / Generic mfg.
[VIRTUAL] General pharmacodynamics algorithm-based clinical protocol design with two to three dose-data points for single-drug, and ten data points for two-drug-combination synergy quantification, using computer simulation for digitalized data analysis and conclusions (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_155;
This report reaffirm Example 2 with the same drug combos against MX-1 mammary carcinoma xenograft in nude mice, using only 10 data points, which showed similar synergy at ED75 to ED97, CI= 0.82-0.79 for MX-1, and CI= 0.98-0.64 for HCT-116. In conclusion, the MAL-PD/BD and its equations, algorithms and computer simulation provide a rigorous, cost-effective, automated, quantitative biomedical R and D and general drug evaluation guidance in clinical trial design and data analysis, that save resources, time and efforts.
- | T900607 / Amgen
Journal: Chemical and biological properties of new sealant-use cement materials. (Pubmed Central) - Dec 20, 2019
In conclusion, the MAL-PD/BD and its equations, algorithms and computer simulation provide a rigorous, cost-effective, automated, quantitative biomedical R and D and general drug evaluation guidance in clinical trial design and data analysis, that save resources, time and efforts. Three of four newly developed GICs modified with calcium, phosphate and fluoride ions were found to be superior to other sealant materials.
- | T900607 / Amgen
Trial completion: T900607 in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: University Hospitals Seidman Cancer Center
Three of four newly developed GICs modified with calcium, phosphate and fluoride ions were found to be superior to other sealant materials. Active, not recruiting --> Completed
- | T900607 / Amgen
Trial completion: T900607 in Treating Patients With Gastroesophageal Junction Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: University Hospitals Seidman Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- TTP607 / vTv Therapeutics
Enrollment change, Metastases: TTP607 in Refractory Solid Malignancies (clinicaltrials.gov) - Jul 26, 2012
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=40 --> 0